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Primary Signet-Ring Carcinoma (SRC) of the Lung
A Population-Based Epidemiologic Study of 262 Cases with
Comparison to Adenocarcinoma of the Lung
Sai-Hong Ignatius Ou, MD, PhD,*†‡ Argyrios Ziogas, PhD,†‡ and Jason A. Zell, DO, MPH*†‡
Background: The presence of signet-ring cell component has been
described as a prominent feature of EML4-ALK positive non-small
cell lung cancer. We investigated the clinicopathologic features and
survival outcome of primary signet-ring carcinoma (SRC) of the
lung with comparison to adenocarcinoma of the lung.
Methods: Retrospective population-based analysis of histologically
diagnosed primary SRC of the lung in the California Cancer Reg-
istry between 1989 and 2006 with comparison with adenocarcinoma
of the lung.
Results: Two hundred sixty-two histologically diagnosed primary
SRC of the lung were compared to 50,089 patients with lung
adenocarcinoma. Patients with primary SRC of the lung were
significantly younger than patients with adenocarcinoma, with a
significantly higher proportion of poorly differentiated tumor and
stage IV disease. There was no difference in the distribution of
gender and ethnicity among patients with SRC when compared to
patients with adenocarcinoma. Subset analysis of patients with
available smoking status revealed never smokers comprised a sig-
nificantly higher proportion of patients with SRC (30.8%) when
compared to patients with adenocarcinoma (11.0%; p  0.0013).
Never smokers with SRC tended to be younger with a trend to
improved survival (median age  55 years, median overall survival
[OS]  8 months) than ever smokers with SRC (median age  59
years, median OS  4.5 months). Patients with SRC had decreased
OS (versus adenocarcinoma; unadjusted hazard ratio  1.507; 95%
confidence interval: 1.326–1.714; p  0.0001) and was an indepen-
dent unfavorable prognostic factor by multivariate analysis (versus
adenocarcinoma, hazard ratio 1.214, 95% confidence interval:
1.068–1.381; p  0.0030).
Conclusions: Primary SRC of the lung is a rare subtype of adeno-
carcinoma, carries a worse prognosis when compared to adenocar-
cinoma and shares many of the recently identified clinicopathologic
characteristics ascribed to EML4-ALK positive non-small cell lung
cancer.
Key Words: Signet-ring carcinoma of the lung, Prognosis, Califor-
nia Cancer Registry, Epidemiology, Smoking status, EML4-ALK
NSCLC.
(J Thorac Oncol. 2010;5: 420–427)
Primary signet-ring carcinoma (SRC) of the lung is a raresubtype of adenocarcinoma of the lung. It was initially
described in 1989 that SRC can exist as a primary tumor of
the lung.1 Kish et al.1 described five cases of primary SRC of
the lung as moderately to poorly differentiated carcinomas
with abundant extracellular mucin production, and the signet-
ring cell components ranged from 10 to 50% of the total
tumor volume. Subsequently, primary SRC of the lung was
recognized in the third edition of the World Health Organi-
zation classification system as a histologic subtype of lung
carcinoma.2
One of the recent advances in lung cancer research is
the discovery of EML4-ALK translocation in non-small cell
lung cancer (NSCLC) resulting in the formation of fusion of
echinoderm microtubule-associated protein-like 4 on chro-
mosome 2 and anaplastic lymphoma kinase on chromosome
5.3,4 It is postulated that the basic domain of EML4 resulted
in dimerization/oligomerization and constitutive activation of
the EML4-ALK fusion kinase.3 Furthermore, a small mole-
cule ALK inhibitor has been shown to have clinical activity
in patients with lung cancer positive for the EML4-ALK
translocation.5,6 Two recent reports demonstrated that a high
proportion of EML4-ALK positive NSCLC tumors in North
America had components of SRC (10%).7,8 To date, only a
few case series of primary SRC of the lung have been
reported in the literature1,9–12 with a total of fewer than 100
cases reported. Thus, much remain unknown about the clin-
icopathologic features and survival outcomes of primary SRC
of the lung in comparison to adenocarcinoma of the lung.
Thus, we performed a population-based study using the
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California Cancer Registry (CCR) to analyze the clinicopath-
ologic features, survival outcomes, and prognostic signifi-
cance of primary SRC of the lung with comparison with lung
adenocarcinoma. Furthermore, we analyzed a subset of pa-
tients with known smoking status as the majority of EML4-
ALK patients in prior reports were never smokers.7,8,13–15
MATERIALS AND METHODS
Population
This was a retrospective study involving analysis of
data from the statewide CCR. Patients with primary SRC of
the lung and adenocarcinoma diagnosed between 1989 and
2006 with complete follow-up data were included in the
study. The third edition of the International Code of Disease
(ICD-0-3) was used for abstracting the histologies. Adeno-
carcinoma (ICD-0-3 code 8140) and SRC (ICD-0-3 code
8490) were abstracted. Only histologically dignosed adeno-
carcinoma and SRC of the lung were included in the study.
Because this study compared and contrasted the clinicopath-
ologic features and survival outcomes between patients with
SRC and adenocarcinoma, we did not include any adenocar-
cinoma subtypes such as acinar, papillary, fetal, or scirrhous
adenocarcinoma. In addition, we did not include any mixed
adenocarcinoma (ICD-0-3 codes 8255 and 8323) in the anal-
ysis. American Joint Committee on Cancer (AJCC) stages
were derived according to the sixth edition AJCC staging
system using available clinical and pathologic tumor, node,
metastasis data from the cancer registry. Patient demographic
data including age, gender, surgery, radiation, and chemo-
therapy given during the first course of therapy and clinico-
pathologic data such as histologic differentiation were ab-
stracted using Surveillance, Epidemiology, and End Results
codes. Ethnicity was abstracted using CCR codes.
For subgroup analysis of patients with smoking status
available, we again performed retrospective analysis of pa-
tients with adenocarcinoma (ICD-0-3 code 8140) and SRC of
the lung (ICD-0-3 code 8490) histologically diagnosed be-
tween 1991 and 2005 from the Cancer Surveillance Programs
of Orange, Imperial, and San Diego counties (CSPOC/SAN-
DIOCC databases) of the CCR. Smoking status was ab-
stracted by examining individual patient text file using a
customized text-mining program, as previously reported.16,17
Statistical Analyses
Comparisons of demographic, clinical, and pathologic
variables were made for patients with NSCLC, using 2 or
Fisher’s exact test for nominal variables and the Student t test
for continuous variables. Comparison of nonparametric val-
ues across two groups was done using Wilcoxon rank sum
test. Univariate survival rate analyses were estimated using
the Kaplan-Meier method, with comparisons made between
groups by the log-rank test. Cox proportional hazards mod-
eling using time since diagnosis was performed. All statistical
analyses were conducted using SAS 9.2 statistical software
(SAS Institute, Inc., Cary, NC). Statistical significance was
assumed for a two-tailed p value less than 0.05.
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (IRB #2007-6078).
RESULTS
Patient Characteristics
A total of 50,351 patients with lung adenocar-
cinoma diagnosed between 1989 and 2006 were analyzed,
including only 262 primary SRC of the lung. For compar-
ison, there were 7266 cases of bronchioloalveolar carci-
noma (ICD-0-3 codes 8250-6254), 1241 cases of papillary
adenocarcinoma (ICD-0-3 code 8260), 379 cases of acinar
cell carcinoma (ICD-0-3 code 8550), and 1 case of fetal
adenocarcinoma (ICD-0-3 code 8333) histologically diag-
nosed during the study period (1989–2006).
The median age of all patients was 67 years (95%
confidence interval [CI]: 46–83), and the median follow-up
time was 9 months (95% CI: 1–109). The median age of
patients with SRC was significantly younger than patients
with adenocarcinoma (64 versus 67 years; p  0.0001). The
proportion of patients with SRC younger than 40 years was
5.0% as compared with 1.3% of patients with adenocarci-
noma. Fifty percent of the patients with SRC had poorly
differentiated carcinoma, which was significantly higher than
patients with adenocarcinoma (43.4%, p  0.0001). More-
over, significantly more patients with SRC (49.2%) presented
with stage IV disease compared with patients with adenocar-
cinoma (36.8%, p  0.0001). There were no differences in
the distribution of SRC by gender or among the four major
ethnicities when compared with patients with adenocarci-
noma. There was no difference in the proportion of patients
with SRC diagnosed among the three periods of diagnosis
compared with patients with adenocarcinoma. Clinicopatho-
logic characteristics of these patients are displayed in Table 1.
Univariate Survival Analysis
Among all patients, overall survival (OS) of adenocar-
cinoma patients was significantly improved over patients with
SRC (Figure 1). The OS of adenocarcinoma was also signif-
icantly improved over SRC among male and female patients,
among white and African American patients, among patients
with moderately and poorly differentiated tumors, among all
three periods of diagnosis and was independent of whether
patients received chemotherapy or not. Although the OS of
adenocarcinoma was numerically greater than SRC among
other individual categories, such differences were not statis-
tically significant. The median OS time and unadjusted haz-
ard ratios (HRs) are listed in Table 2.
We further analyzed the potential contribution of che-
motherapy in stage IV patients with adenocarcinoma and
SRC during the three periods of diagnosis. The median OS of
stage IV patients according to the three periods of diagnosis
stratified by histology and according to chemotherapy re-
ceived or not were listed in Table 3.
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Multivariate Analysis
After factoring in age, gender, ethnicity, AJCC stage,
period of diagnosis, tumor differentiation, and treatment
(surgery, radiation, and chemotherapy), SRC (versus ade-
nocarcinoma) was associated with increased risk of death
(HR  1.214; 95% CI: 1.068–1.381; p  0.0030) (Table
4). Favorable prognostic factors included early stage,
younger age, female gender, Asian ethnicity, well differ-
entiated tumor, and treatment with surgery, radiation, and
chemotherapy.
We also analyzed the prognostic significance of SRC
histology among stage IV patients. SRC (versus adenocarci-
noma) remained an independent unfavorable prognostic fac-
tor among stage IV patients (HR  1.279; 95% CI: 1.073–
1.524; p  0.0060) (Table 5).
Subgroup Analysis of Patients with Known
Smoking Status
Because the CCR does not contain smoking data, we
analyzed patients diagnosed within a regional CCR database
where we have available data to abstract smoking status. For
this subset analysis, we identified a total of 26 cases of
primary SRC of the lung and 5919 cases of adenocarcinoma
of the lung who were all histologically diagnosed from 1991
to 2005 where the smoking status of the patients was known.
A total of 30.8% of the patients with SRC compared with
11.0% of the patients with adenocarcinoma were never smok-
ers (p  0.0013). The median age of patients with SRC who
were never smokers was 4 years younger than patients with
SRC who were ever smokers (55 versus 59 years), although
the difference was not statistically significant due to limited
number of cases. The complete list of clinicopathologic
features of the patients by smoking status is listed in Table 6.
The OS of patients with adenocarcinoma who were never
smokers was 14 months compared with 12 months for pa-
tients with adenocarcinoma who were ever smokers (p 
0.9097). The OS of patients with SRC who were never
smokers was 8 months compared with 4.5 months for patients
with SRC who were ever smokers (p  0.9742).
TABLE 1. Clinicopathologic Characteristics of Patients with
Adenocarcinoma and Signet-Ring Carcinoma (SRC) NSCLC
(N  50,351)
Adenocarcinoma SRC p
N (%) 50089 (99.5) 262 (0.5)
Median age of diagnosis
(mean age)
(95% CI) (yr)
67 (65)
(46–83)
64 (62)
(40–80)
0.0001a
Median follow-up time
(mo) (95% CI) 9 (1–109) 5.5 (1–58)
0.0001a
Period of diagnosis
1989–1994 17346 (34.6) 75 (28.6)
1995–2000 16401 (32.7) 92 (35.1)
2001–2006 16342 (32.6) 95 (36.3) 0.1214
Gender
Male 26062 (52.0) 146 (55.7)
Female 24027 (48.0) 116 (44.3) 0.2326
Age category (yr)
0–39 666 (1.3) 13 (5.0)
40–49 3516 (7.0) 24 (9.2)
50–59 9852 (19.7) 64 (24.4)
60–69 16198 (32.3) 80 (30.5)
70–79 14822 (29.6) 65 (24.8)
80 5035 (10.1) 16 (6.1) 0.0001
Ethnicity
White 37677 (75.2) 190 (72.5)
African American 3695 (7.4) 19 (7.3)
Asian 4215 (8.4) 21 (8.0)
Hispanic 4310 (8.6) 31 (11.8)
Other 192 (0.4) 1 (0.4) 0.4845
Tumor differentiation
Well 2635 (5.3) 2 (0.8)
Moderate 11484 (22.9) 24 (9.2)
Poor 21743 (43.4) 131 (50.0)
Undifferentiated 794 (1.6) 3 (1.2)
Unknown 13433 (26.8) 102 (38.9) 0.0001
AJCC stage
I 9174 (18.3) 16 (6.1)
II 2610 (5.2) 13 (5.0)
III 8315 (16.6) 54 (20.6)
IV 18409 (36.8) 129 (49.2)
Unknown 11581 (23.1) 50 (19.1) 0.0001
Surgery
Yes 17951 (35.8) 43 (16.4)
No 32058 (64.0) 219 (83.6)
Unknown 80 (0.2) 0 (0.0) 0.0001
Radiation
Yes 20624 (41.2) 111 (42.4)
No 29461 (58.8) 151 (57.6)
Unknown 4 (0.01) 0 (0.0) 0.9172
Chemotherapy
Yes 15794 (31.5) 130 (49.6)
No 33185 (66.3) 128 (48.9)
Unknown 1110 (2.2) 4 (1.5) 0.0001
a Wilcoxon rank sum test.
CI, confidence interval; NSCLC, non-small cell lung cancer.
FIGURE 1. Kaplan-Meier survival curves of lung adenocarci-
noma and primary lung signet ring carcinoma.
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DISCUSSION
The recent discovery of the EML4-ALK translocation in
lung cancer3,4 and the rapid development of an ALK inhibitor
with substantial clinical activity that targets this particular
EML4-ALK5,6 translocation have generated excitement in
understanding the clinicopathologic features and survival of
patients with EML4-ALK NSCLC. Two recent publications
on the clinicopathologic characteristics of EML4-ALK
NSCLC in western population revealed a high proportion of
these tumor contained signet-ring cell morphology. Given the
limited numbers of EML4-ALK positive NSCLC identified so
far, we performed an epidemiologic study of primary SRC of
the lung to determine whether there are clinicopathologic
features of primary SRC are in congruence with the clinico-
pathologic features reported for patients with EML4-ALK
NSCLC.
TABLE 2. Comparison of Survival Between Patients with Adenocarcinoma and Signet-
Ring Carcinoma (SRC) by Individual Clinicopathologic Category
Adenocarcinoma
Median OS (mo)
(95% CI)
SRC
Median OS (mo)
(95% CI)
Unadjusted HR
(95% CI) p
Overall 10 (10–11) 6 (5–6) 1.507 (1.326–1.714) 0.0001
Gender
Male 9 (8–9) 5 (4–6) 1.435 (1.212–1.699) 0.0001
Female 13 (13–14) 7 (5–8) 1.582 (1.300–1.926) 0.0001
Age category (yr)
0–39 10 (9–11) 9 (5–16) 1.300 (0.715–2.363) 0.3900
40–49 11 (10–12) 6 (4–14) 1.444 (0.941–2.218) 0.0930
50–59 12 (12–13) 5 (3–8) 1.459 (1.122–1.897) 0.0048
60–69 12 (11–12) 6 (5–9) 1.594 (1.262–2.012) 0.0001
70–79 9 (9–10) 5 (3–7) 1.679 (1.303–2.164) 0.0001
80 6 (6–7) 3 (1–6) 1.611 (0.986–2.632) 0.0570
Period of diagnosis
1989–1994 9 (9–10) 5 (3–7) 1.619 (1.290–2.031) 0.0001
1995–2000 10 (10–11) 5 (4–7) 1.549 (1.258–1.908) 0.0001
2001–2006 12 (12–13) 6 (5–8) 1.382 (1.095–1.745) 0.0065
Ethnicity
White 11 (10–11) 6 (5–7) 1.541 (1.326–1.791) 0.0001
African American 9 (9–10) 3 (1–7) 2.714 (1.368–3.455) 0.0010
Asian 13 (12–14) 5 (3–29) 1.218 (0.756–1.962) 0.4172
Hispanic 9 (8–9) 9 (4–16) 1.158 (0.799–1.680) 0.4389
Tumor differentiation
Well 32 (30–36) 16 (16–NR) 0.652 (0.092–4.618) 0.6686
Moderate 23 (22–24) 7 (6–8) 2.108 (1.359–3.268) 0.0009
Poor 10 (9–10) 6 (5–8) 1.337 (1.116–1.602) 0.0016
Undifferentiated 9 (8–10) 13 (2–26) 1.192 (0.383–3.707) 0.7614
Unknown 6 (6–7) 4 (3–6) 1.195 (0.974–1.465) 0.0872
AJCC stage
I 67 (65–70) 57 (16–132) 1.261 (0.656–2.424) 0.4876
II 26 (25–28) 37 (8–98) 0.901 (0.450–1.804) 0.7678
III 11 (10–11) 6 (4–9) 1.294 (0.974–1.718) 0.0755
IV 4 (4–5) 4 (3–5) 1.167 (0.980–1.397) 0.0836
Unknown 12 (11–12) 6 (4–8) 1.391 (1.035–1.870) 0.0287
Surgery
Yes 45 (43–46) 32 (16–54) 1.403 (0.987–1.995) 0.0594
No 5 (5–6) 5 (4–6) 1.135 (0.989–1.302) 0.0718
Radiation
Yes 8 (8–9) 6 (5–8) 1.161 (0.958–1.408) 0.1279
No 14 (14–15) 5 (3–6) 1.743 (1.468–2.069) 0.0001
Chemotherapy
Yes 11 (10–11) 7 (6–9) 1.242 (1.033–1.493) 0.0212
No 10 (10–11) 3 (2–5) 1.720 (1.434–2.063) 0.0001
SRC, signet–ring carcinoma; NR, not reached; AJCC, American Joint Committee on Cancer; OS, overall survival; CI,
confidence interval.
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In this study, we observed that primary SRC of the lung
is a rare subtype of adenocarcinoma of the lung in agreement
with literature,1,9–12 as we only identified 262 histologically
diagnosed cases of primary SRC of the lung in the CCR
during a period of 18 years. Primary SRC tumors are pre-
dominantly poorly differentiated tumors. Patients with pri-
mary SRC of the lung are significantly younger than patients
with adenocarcinoma. Moreover, the proportion of patients
with SRC younger than 40 years was 5.0% as compared with
1.3% for patients with adenocarcinoma. Patients with SRC
presented with a higher proportion of stage 4 disease than
TABLE 3. Univariate Analysis of Overall Survival of Stage IV Adenocarcinoma and Signet-Ring Carcinoma (SRC) According to
Period of Diagnosis and Chemotherapy Received
Chemotherapy
Period 1 (1989–1994) Period 2 (1995–2000) Period 3 (2001–2006)
No Yes p No Yes p No Yes p
Stage IV adenocarcinoma
Median OS (mo) 3 6 0.0001 3 7 0.0001 2 9 0.0001
Stage IV SRC
Median OS (mo) 2 5 0.2364 1 6 0.0001 2 7 0.0003
OS, overall survival.
TABLE 4. Cox Model for Overall Survival for All Patients
Hazard
Ratio
95% Confidence
Interval p
Histology
Adenocarcinoma 1.000
Signet-ring cell carcinoma 1.214 1.068–1.381 0.0030
Age (yr) 1.011 1.011–1.012 0.0001
Gender
Male 1.000
Female 0.844 0.828–0.861 0.0001
Ethnicity
White 1.000
African American 0.991 0.955–1.028 0.6213
Asian 0.796 0.767–0.825 0.0001
Hispanic 0.998 0.984–1.033 0.9076
Period of diagnosis
1989–1994 1.000
1995–2000 0.942 0.920–0.964 0.0001
2001–2006 0.808 0.787–0.830 0.0001
Tumor differentiationa
Well 1.000
Moderate 1.219 1.158–1.283 0.0001
Poor 1.438 1.369–1.510 0.0001
Undifferentiated 1.446 1.325–1.577 0.0001
AJCC stagea
I 1.000
II 1.835 1.742–1.933 0.0001
III 2.313 2.220–2.410 0.0001
IV 3.624 3.481–3.772 0.0001
Surgerya
No 1.000
Yes 0.312 0.303–0.322 0.0001
Radiationa
No 1.000
Yes 0.859 0.841–0.878 0.0001
Chemotherapya
No 1.000
Yes 0.657 0.642–0.673 0.0001
a Unknown category included in the Cox multivariate analysis but data not shown.
AJCC, American Joint Committee on Cancer.
TABLE 5. Cox Model for Overall Survival for Stage IV
Patients
Hazard
Ratio
95% Confidence
Interval p
Histology
Adenocarcinoma 1.000
Signet-ring cell carcinoma 1.279 1.073–1.524 0.0060
Age (yr) 1.007 1.006–1.008 0.0001
Gender
Male 1.000
Female 0.873 0.847–0.899 0.0001
Ethnicity
Caucasian 1.000
African American 1.016 0.961–1.075 0.5730
Asian 0.765 0.725–0.807 0.0001
Hispanic 0.962 0.915–1.012 0.1325
Period of diagnosis
1989–1994 1.000
1995–2000 0.963 0.928–1.000 0.0486
2001–2006 0.845 0.812–0.879 0.0001
Tumor differentiationa
Well 1.000
Moderate 1.217 1.107–1.338 0.0001
Poor 1.371 1.253–1.500 0.0001
Undifferentiated 1.416 1.225–1.637 0.0001
Surgerya
No 1.000
Yes 0.401 0.374–0.428 0.0001
Radiation
No 1.000
Yes 0.820 0.795–0.846 0.0001
Chemotherapya
No 1.000
Yes 0.549 0.531–0.567 0.0001
a Unknown category included in the Cox multivariate analysis but data not shown.
Ou et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer424
patients with adenocarcinoma. There was no difference in the
distribution of primary SRC of the lung by gender or by
ethnicity when compared with adenocarcinoma of the lung.
Case series of EML4-ALK-positive NSCLC from Asia,13–15
European,19 and North America7,8 all reported the percentage
of EML4-ALK NSCLC to be 5 to 10% of all lung adenocar-
TABLE 6. Subgroup Analysis of Clinicopathologic Characteristics of Patients with Adenocarcinoma and
Signet-Ring Carcinoma (SRC) NSCLC with Known Smoking Status (N  5919)
Adenocarcinoma
p
SRC
pEver Smoker Never Smoker Ever Smoker Never Smoker
N (%) 5271 (89.0) 648 (11.0) 18 (69.2) 8 (30.8)
Median age of diagnosis
(95% CI) (yr)
67 (47–82) 68 (41–85) 0.4258a 59 (42–84) 55 (40–87) 0.4199a
Median follow-up time
(mo) (95% CI)
11 (1–110) 12 (1–96) 0.4796a 4 (0–124) 8 (2–29) 0.3001a
Period of diagnosis
1989–1994 1860 (35.3) 200 (30.9) 6 (33.3) 4 (50.0)
1995–2000 1815 (34.4) 211 (32.6) 8 (44.4) 2 (25.0)
2001–2006 1596 (30.3) 237 (36.6) 0.0037 4 (22.2) 2 (25.0) 0.6179
Gender
Male 2788 (52.9) 218 (33.6) 10 (55.6) 3 (37.5)
Female 2483 (47.1) 430 (66.4) 0.0001 8 (44.4) 5 (62.5) 0.3954
Age category (yr)
0–39 53 (1.0) 28 (4.3) 0 (0.0) 0 (0.0)
40–49 337 (6.4) 65 (10.0) 3 (16.7) 3 (37.5)
50–59 986 (18.7) 116 (17.9) 6 (33.3) 2 (25.0)
60–69 1803 (34.2) 148 (22.8) 5 (27.8) 2 (25.0)
70–79 1592 (30.2) 191 (29.5) 3 (16.7) 0 (0.0)
80 500 (9.5) 100 (15.4) 0.0001 1 (5.6) 1 (12.5) 0.5810
Ethnicity
White 4454 (84.5) 425 (65.6) 18 (100.0) 4 (50.0)
African American 164 (3.1) 14 (2.2) 0 (0.0) 0 (0.0)
Asian 284 (5.4) 132 (20.4) 0 (0.0) 2 (25.0)
Hispanic 367 (7.0) 77 (11.9) 0 (0.0) 2 (25.0)
Other 2 (0.04) 0 (0.0) 0.0001 0 (0.0) 0 (0.0) 0.0049
Tumor differentiation
Well 306 (5.8) 55 (8.5) 0 (0.0) 0 (0.0)
Moderate 1303 (24.7) 189 (29.2) 2 (11.1) 0 (0.0)
Poor 2414 (45.8) 228 (35.2) 9 (50.0) 6 (75.0)
Undifferentiated 65 (1.2) 3 (0.5) 0 (0.0) 0 (0.0)
Unknown 1183 (22.4) 173 (26.7) 0.0001 7 (38.9) 2 (25.0) 0.4071
AJCC stage
I 1160 (22.0) 115 (17.8) 2 (11.1) 0 (0.0)
II 331 (6.3) 33 (5.1) 0 (0.0) 0 (0.0)
III 924 (17.5) 98 (15.1) 5 (27.8) 2 (25.0)
IV 2221 (42.1) 316 (48.8) 10 (55.6) 6 (75.0)
Unknown 635 (12.1) 86 (13.3) 0.0053 1 (5.6) 0 (0.0) 0.6393
Surgery
Yes 2258 (42.8) 236 (36.4) 4 (22.2) 0 (0.0)
No 3013 (57.2) 412 (63.6) 0.0018 14 (77.8) 8 (100.0) 0.1472
Radiation
Yes 2190 (41.6) 265 (40.9) 6 (75.0) 7 (38.9)
No 3081 (58.5) 383 (59.1) 0.7502 2 (25.0) 11 (61.1) 0.0892
Chemotherapy
Yes 1580 (31.9) 265 (40.9) 8 (44.4) 7 (87.5)
No 3573 (67.8) 383 (59.1) 10 (55.6) 1 (12.5)
Unknown 18 (0.3) 0 (0.0) 0.0001 0 (0.0) 0 (0.0) 0.0403
a Wilcoxon rank sum test.
CI, confidence interval; AJCC, American Joint Committee on Cancer; NSCLC, non-small cell lung cancer.
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cinoma with no significance variation in incidence among
various ethnicities.
Patients with SRC also had significant decreased OS
when compared with patients with adenocarcinoma in nearly
all categories examined (Table 2). Furthermore, SRC is
independently associated with poor prognosis by multivariate
analysis after accounting for differences in age, gender,
ethnicity, period of diagnosis, tumor differentiation, stage,
and treatment. Case reports and case series of lung have
reported that primary SRC of the lung had poorer survival
compared with other non-SRC NSCLC,1,11,12 and that the
higher the proportion of the signet-ring cells, the poorer the
prognosis.11
We performed a subgroup analysis of a regional CCR
database where we were able to abstract smoking status16,17
(the national Surveillance, Epidemiology, and End Results
database nor the CCR contains any information on smoking
status). In these subset analyses, we identified 26 case of
histologically diagnosed primary SRC of the lung diagnosed
between 1991 and 2005 with known smoking status. Consis-
tent with literature,11 the proportion of never smokers among
patients with SRC (30.8%) was significantly higher than
patients with adenocarcinoma (11.0%; p  0.0013). Patients
with SRC who were never smokers tend to be younger than
their ever-smoking counterparts. Of note, the median age of
never smokers with primary SRC of the lung was 55 years,
which is within the range of median age (51–59 years)7,8,13,15
reported for patients with EML4-ALK NSCLC. Moreover, the
proportion of never smokers with SRC younger than 50 years
was 37.5% in this study, which is similar to the proportion
(36.0%)15 reported for patients with EML4-ALK NSCLC.
Finally, the survival of patients with SRC who were never
smokers was numerically superior to their counterparts who
were ever smokers although this difference was not statisti-
cally significant.
One limitation of this study is the likely underreporting
of primary SRC of the lung in cancer registries. The signif-
icance of signet-ring cell component in adenocarcinoma of
the lung besides portending a generally poor survival was not
truly appreciated until the recent studies linking SRC to
EML4-ALK NSCLC.7,8 Thus, SRC component in lung ade-
nocarcinoma may have been underreported by pathologists
and not specifically abstracted and coded into tumor registry
databases. Another limitation of this study is that there is no
central pathology review, so the proportion of signet-ring cell
component within each tumor is unknown because SRC was
defined by individual pathologist. Therefore, we could not
address whether the proportion of signet-ring cell component
adversely affects the OS of primary SRC of the lung as
reported.11,12 Furthermore, there is no consensus on what
percentage of signet-ring cell component within adenocarci-
noma defines NSCLC as primary SRC of the lung. World
Health Organization generally defines a histologic subtype of
adenocarcinoma as at least 10% of the tumor. Reviewing
published literature to date, various reports have used a
signet-ring cell component ranging from 5,11,12 10,1,7,8 30,10
to 75%9 as a significant cutoff. We attempted to partially
address this particular limitation by analyzing only tumors
that were histologically diagnosed but not cytologically,
which should allow better identification of the signet-ring cell
component. Previously, we have shown that cytologically
diagnosed NSCLC had a higher proportion of carcinoma
NOS (not otherwise specified) and that advanced NSCLC
cytologically diagnosed carried an independent poor progno-
sis when compared with advanced NSCLC histologically
diagnosed.20 Finally, although we revealed many clinicopath-
ologic features that are similar between SRC of the lung and
EML4-ALK NSCLC, we did not and could not show that the
presence of EML4-ALK fusion transcripts by polymerase
chain reaction or the presence of EML4-ALK fusion protein
by immunohistochemistry within SRC of the lung or the
presence of ALK translocation in SRC of the lung by flores-
cence in situ hybridization. Further large-scale studies will
have to be carried out in primary SRC of the lung to determine
the percentage of EML4-ALK positivity in these rare adenocar-
cinoma subtypes.
The advantage of this study is that it is one of the
largest studies of SRC where we can analyze the prognostic
significance of SRC of the lung by accounting for other
independent prognostic factors. Despite that there were only
262 cases, we were able to show by multivariate analysis that
SRC is a significant independent unfavorable prognostic
factor when compared to adenocarcinoma. Another advan-
tage is that we were able to analyze the distribution of
primary SRC of the lung among the four major ethnicities
with comparison with adenocarcinoma.
In conclusion, we performed a retrospective popula-
tion-based study of primary SRC of the lung. However, the
absolute number of SRC cases recorded in the tumor registry
is low, and we hope that the recent linkage of signet-ring cell
component to EML4-ALK NSCLC will raise awareness of
this unique histologic NSCLC subtype. Increased awareness
and attention from pathologists is required to identify the
signet-ring cell component within lung adenocarcinomas, and
pathologists must reach a consensus on what percentage of
signet-ring cell component within adenocarcinoma constitutes
primary SRC of the lung, so that we have better epidemiologic
data on the clinocopathologic features and survival outcomes of
primary SRC of the lung. Finally, it is important to note that not
all reports of EML4-ALK NSCLC revealed signet-ring cell
component. Inamura et al.15 reported that EML4-ALK NSCLC
presented with acinar carcinoma features, especially variant 2 of
the EML4-ALK fusion transcript. Indeed 4 of the 20 EML4-ALK
NSCLC cases reported in North America also had predomi-
nantly acinar cell pattern.7,8 Thus, it remains important to con-
tinue to describe and analyze the clinicopathologic features and
survival outcomes of other uncommon histologic NSCLC sub-
types as basic research discoveries and translational research
advancements lead to areas of lung cancer than have been
understudied in the past.
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